腹腔灌注化疗在胃癌综合治疗中的价值  

The role of intraperitoneal chemotherapy in the treatment of gastric cancer

作　　者：程曦 方勇[1] Cheng Xi;Fang Yong(Department of Medical Oncology,Sir Run Run Shaw Hospital,Zhejiang University School of Medicine,Hangzhou 310016,China)

机构地区：[1]浙江大学医学院附属邵逸夫医院肿瘤内科,杭州310016

出　　处：《肿瘤综合治疗电子杂志》2020年第3期58-63,共6页Journal of Multidisciplinary Cancer Management(Electronic Version)

摘　　要：腹膜转移是胃癌的主要致死原因。近年来,部分临床研究证实包含腹腔灌注化疗的综合治疗可改善胃癌患者预后,降低根治术后转移风险,也可改善并延长已存在腹膜转移患者的生存时间。更为积极的治疗方法,如腹腔热灌注化疗、腹腔热灌注化疗联合肿瘤细胞减灭术等也具有较好的治疗效果。选择潜在可能获益的患者是获得良好疗效的重要前提。本文回顾近年来腹腔灌注化疗在晚期胃癌综合治疗领域中的研究进展,为今后的研究和临床实践提供参考。Peritoneal metastasis is one of the leading causes of cancer-related deaths of gastric cancer.In recent years,some clinical studies have confirmed that comprehensive treatments containing with intraperitoneal chemotherapy could improve the prognosis of patients with gastric cancer.The comprehensive treatments could reduce the risk of metastasis in patients after radical surgery and improve survival in patients with peritoneal metastases.The aggressive treatments,such as hyperthermic intraperitoneal chemotherapy or hyperthermic intraperitoneal chemotherapy combined with cytoreductive surgery,have good therapeutic effect.Selecting patients who might benefit from the treatments is an important prerequisite for good effect.This paper reviewed the advances in the studies on intraperitoneal chemotherapy of gastric cancer,might provide some help for future researches and clinical practices.

关 键 词：胃癌 腹腔灌注化疗 腹膜转移 

分 类 号：R735.2[医药卫生—肿瘤]